EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 22nd, 2022 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
LIPOXEN TECHNOLOGIES LIMITED, a legal entity incorporated and existing under the laws of United Kingdom, registered at the address: 5th Floor, 15 Whitehall, London SW1A 2DD, United Kingdom, represented by its Director James Parslow, acting pursuant to the Articles of Association, hereinafter referred to as "the Licensor", on the one part, and
CERTAIN INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY BRACKETS AND ASTERISKS (“[***]”), HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K UNDER THE SECURITIES ACT OF 1933, AS AMENDED, BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD...Master Services Agreement • March 22nd, 2022 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
THIS AMENDMENT NUMBER ONE TO THE MASTER SERVICES AGREEMENT (this “Amendment One”), is made effective October 12, 2021 (the “Effective Date) between Xenetic Biosciences, Inc. a Nevada corporation having its place of business at 40 Speen Street, Suite 102, Framingham, Massachusetts 01701 (“Sponsor”) and PJSC Pharmsynthez, a Russian public joint stock company having an address of No 134, Liter 1, Poselok Kuzmolovsky, St. Kapitolovo, Vsevolozhsky Raion, Leningradskaya Oblast, 188663, Russia (“Pharms”). Individually, each of Sponsor and Pharms is a “Party” and collectively, “Parties.”
NOVATION of Agreement on Co-Development and the Terms of Exclusive LicenseNovation of Agreement on Co-Development and the Terms of Exclusive License • March 22nd, 2022 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This Novation of Agreement on Co-Development and the Terms of Exclusive License (the “Agreement”) is made on December 17, 2021 between:
